drugset / Trial / NCT04994002
A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of CERC-006 in adults (aged 18-31 years) with active, moderate to severe complex lymphatic malformations.
Timeline
- Start
- 2021-09-03
- Primary completion
- 2022-06
- Completion
- 2022-06
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OSI-027 | Small molecule | 0.5 mg | Oral |
| Subject | OSI-027 | Small molecule | 1 mg | Oral |